سوق تشخيص سرطان الكبد – المحركات والاتجاهات والفرص وإحصاءات النمو | 2031

  • Report Code : TIPRE00003017
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 181
Buy Now

من المتوقع أن يصل سوق تشخيص سرطان الكبد إلى 15,951.77 مليون دولار أمريكي بحلول عام 2028 من 9,323.14 مليون دولار أمريكي في عام 2021. ومن المتوقع أن ينمو السوق بمعدل نمو سنوي مركب قدره 8.0% خلال الفترة من 2021 إلى 2028.

يبدأ سرطان الكبد في خلايا الكبد. يمكن أن تتشكل أنواع متعددة من السرطان في الكبد. يعتبر سرطان الخلايا الكبدية من أكثر أنواع سرطان الكبد شيوعًا ويبدأ في خلايا الكبد. وفقًا للجمعية الأمريكية لعلم الأورام السريري (ASCO)، فإن حوالي 80% من حالات سرطان الكبد الأولية لدى البالغين هي سرطانات خلايا كبدية. تشمل الأنواع الأخرى من سرطان الكبد الورم الأرومي الكبدي وسرطان القنوات الصفراوية داخل الكبد. وتعتبر هذه أقل شيوعا. يشتمل تشخيص سرطان الكبد على تقنيات مستخدمة لتحديد سرطان الكبد وتأكيده.

رؤى إستراتيجية

يُعزى نمو سوق تشخيص سرطان الكبد إلى ارتفاع معدل انتشار سرطان الكبد وزيادة استثمارات البحث والتطوير. في تطوير اختبارات تشخيصية جديدة. من ناحية أخرى، فإن التكلفة العالية لحلول تشخيص سرطان الكبد المتقدمة تقنيًا تعيق نمو السوق.

المناطق المربحة في سوق تشخيص سرطان الكبد


رؤى السوق< br /> زيادة استثمارات البحث والتطوير في تطوير اختبارات تشخيصية جديدة

تعد القدرة على تشخيص تطور سرطان الكبد بدقة أمرًا بالغ الأهمية لتحديد خيار العلاج المناسب. علاوة على ذلك، اتخذت العديد من الشركات والمنظمات مبادرات هائلة لتطوير وتنفيذ حلول مبتكرة للكشف المبكر عن هذا المرض استجابة للطلب المتزايد. على سبيل المثال، في مارس 2020، حصلت شركة Elecsys GALAD التابعة لشركة Roche Holding AG على حالة الجهاز المتطور من إدارة الغذاء والدواء الأمريكية للكشف المبكر عن شكل متقدم من سرطان الكبد. تجمع الآلة الحاسبة الخاصة بشركة الأدوية السويسرية بين عوامل تشمل العمر والجنس ونتائج العلامات الحيوية للكشف عن سرطان الكبد في المراحل المبكرة، وهو الشكل الأكثر شيوعًا لسرطان الكبد. علاوة على ذلك، تم تصميم درجة Elecsys GALAD لدعم الأطباء من خلال تزويدهم بتشخيص دقيق وفي الوقت المناسب لسرطان الكبد. بلغت نفقات البحث والتطوير (R&D) في عام 2021 14.65 مليار دولار أمريكي وفي عام 2020 بلغت 13.17 مليار دولار أمريكي. ارتفع الإنفاق على البحث والتطوير بنسبة 14% على أساس أساسي، في شركة F. Hoffmann-La Roche Ltd، مدفوعًا في الغالب باستثمارات المرحلة الأخيرة في علاج الأورام وطب العيون والرعاية الصحية الشخصية. وفي عام 2021، بلغ الاستثمار في البحث والتطوير في قسم التشخيص 1,878.92 مليون دولار أمريكي. وبالمثل، في نوفمبر 2019، حصلت شركة EXACT Sciences Corporation على تصنيف اختراق من إدارة الغذاء والدواء (FDA) لاختبارها المعتمد على الدم للكشف المبكر عن سرطان الكبد. بالإضافة إلى ذلك، في يونيو 2020، طور علماء المعاهد الوطنية للصحة (NIH) اختبارات الدم للمساعدة في تحسين فحص سرطان الكبد، بقيادة باحثين في المعهد الوطني للسرطان (NCI). بالإضافة إلى ذلك، في يونيو 2019، تم تصميم CancerSEEK، وهو اختبار خزعة سائلة، من قبل باحثين في جامعة جونز هوبكنز. وتم تصميم الاختبار لتشخيص سرطانات متعددة، بما في ذلك سرطان المعدة والكبد والمبيض والمريء، في مرحلة مبكرة، مما يسهل العلاج المبكر. لذلك، فإن الاستثمارات المتزايدة في مجال البحث والتطوير وتطوير الاختبارات التشخيصية للكشف عن سرطان الكبد تقود سوق تشخيص سرطان الكبد.

رؤى قائمة على النوع

تشخيص سرطان الكبد عالميًا يتم تقسيم السوق، بناءً على النوع، إلى الاختبارات المعملية والتنظير والتصوير والخزعة وغيرها. يتم تقسيم سوق قطاع الاختبارات المعملية إلى اختبارات الدم والمؤشرات الحيوية. استحوذ قطاع الاختبارات المعملية على الحصة الأكبر من السوق في عام 2021. ومع ذلك، من المتوقع أن يسجل قطاع التصوير معدل نمو سنوي مركب قدره 8.5٪ في السوق خلال الفترة المتوقعة.

سوق تشخيص سرطان الكبد حسب النوع – 2021 و2028


الرؤى المستندة إلى المستخدم النهائي

استنادًا إلى المستخدم النهائي، يتم تقسيم السوق العالمية لتشخيص سرطان الكبد إلى مستشفيات ومختبرات تشخيصية ومعاهد أكاديمية وبحثية، ومختبرات CRO. استحوذ قطاع المستشفيات والمختبرات التشخيصية على الحصة الأكبر من السوق في عام 2021 حيث توفر المستشفيات مرافق الرعاية الصحية من خلال المعدات العلمية المتخصصة. يتم تعيين فريق من الموظفين المدربين للتعامل والتحقيق وترميم المشاكل المرتبطة بالعلوم الطبية الحديثة في المستشفى. تعمل فرق البحث الطبية المختلفة باستمرار على إدخال تقنيات مبتكرة تتعلق بطرق التشخيص والأنشطة الأخرى في المجال الطبي. يفضل المرضى عمومًا تلقي علاج سرطان الكبد في المستشفى نظرًا لتوفر خيارات العلاج المتقدمة. المستشفيات هي نقطة الرعاية للمرضى. علاوة على ذلك، من المتوقع أن يسجل نفس القطاع معدل نمو سنوي مركب قدره 8.5% في السوق خلال الفترة المتوقعة.

يعد إطلاق المنتجات والموافقات بمثابة استراتيجيات يتم اعتمادها بشكل شائع من قبل الشركات لتوسيع نطاق تواجدها العالمي وحافظات المنتجات للسيطرة على السوق. الحصة السوقية لتشخيص سرطان الكبد علاوة على ذلك، يركز اللاعبون في السوق على استراتيجية الشراكة لتوسيع قاعدة عملائهم، والتي بدورها تسمح لهم بالحفاظ على اسم علامتهم التجارية على مستوى العالم. من المتوقع أن تزدهر الحصة السوقية لتشخيص سرطان الكبد مع تطوير منتجات مبتكرة جديدة من قبل اللاعبين في السوق.

ملفات الشركة

  • Abbott
  • BioMerieux SA
  • ف. HOFFMANN-LA ROCHE LTD
  • Illumina, Inc.
  • Koninklijke Philips NV
  • QIAGEN
  • Siemens Healthineers AG
  • شركة THERMO FISHER SCIENTIFIC INC.
  • GE Healthcare
  • Perspectum
  • Helio, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are liver cancer diagnostics?

The abnormal proliferation of cells in the body is referred to as cancer. Cancer of the liver starts in the cells of the liver. The liver can develop a variety of cancers. Hepatocellular carcinoma is the most prevalent type of liver cancer, and it starts in the hepatocyte. Some liver cancers can be detected through screening in persons who are at high risk but do not have symptoms, but most liver cancers are discovered when they produce symptoms. To detect liver disease, a series of blood tests known as liver function tests and imaging studies are employed.

What are the driving factors for the liver cancer diagnostics market across the globe?

Key factors that are driving the growth of this market are the rising prevalence of liver cancer and rising R&D investments for the development of novel diagnostic testing are expected to boost the market growth for liver cancer diagnostics over the years.

What is the market CAGR value of the liver cancer diagnostics market during the forecast period?

The CAGR value of the liver cancer diagnostics market during the forecasted period of 2021-2028 is 8.0%.

Which type led the liver cancer diagnostics market?

The laboratory tests segment held the largest share of the market in the global liver cancer diagnostics market and held the largest market share of 39.61% in 2021.

Which end user held the largest share in the liver cancer diagnostics market?

The hospitals and diagnostic laboratories segment dominated the global liver cancer diagnostics market and accounted for the largest market share of 48.56% in 2021.

Who are the key players in the Liver Cancer Diagnostics market?

The liver cancer diagnostics market majorly consists of players such as Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; Helio, Inc amongst others.

Which are the top companies that hold the market share in liver cancer diagnostics market?

Koninklijke Philips N.V. and Siemens Healthineers AG are the top two companies that hold huge market shares in the liver cancer diagnostics market.

Which region is expected to witness significant demand for the liver cancer diagnostics market in the coming years?

The North America region secures a substantial share of the global liver cancer diagnostics market. The growth of the market in the region is attributed by the rising prevalence of liver cancer. In North America, the US is the largest market for liver cancer diagnostics. The growth of this market is primarily driven by the growing prevalence of liver cancer diseases, technological advancements and developments in the US are going to accelerate the growth of this market in this country.

What is the COVID 19 impact on the Liver Cancer Diagnostics market in the coming years?

The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented problems to healthcare systems, and patients with liver cancer (LC) may have been particularly affected. COVID-19 may aggravate pre-existing chronic liver damage in HCC patients, complicating cancer treatment. Cancer patients, especially those who have just completed treatment, are at a higher risk of infection and have a poorer prognosis. The first wave of the COVID-19 epidemic had a huge influence on liver cancer patients' normal care. Patients' outcomes may have been considerably harmed as a result of changes to screening, diagnostic, and treatment algorithms. The benefits and drawbacks of the tactics used will be reported through ongoing data collecting and future analysis, assisting future decision-making. However, in the long run, as the vaccination schedule is established and the transmission rate decreases, healthcare systems will return to normal and is expected to experience increased demand for liver cancer diagnostics.

The List of Companies - Liver Cancer Diagnostic Market

  1. Abbott
  2. BioMerieux SA
  3. F. HOFFMANN-LA ROCHE LTD
  4. Illumina, Inc.
  5. Koninklijke Philips N.V
  6. QIAGEN
  7. Siemens Healthineers AG
  8. THERMO FISHER SCIENTIFIC INC.
  9. GE Healthcare
  10. Perspectum
  11. Helio, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports